US 7,608,411 B2 · Prostaglandin receptor EP1

Abstract

(1) A novel polypeptide prostaglandin E receptor, (2) a cDNA encoding the polypeptide and a fragment selectively hybridized to the sequence of the cDNA, (3) a replication or expression vector carrying the DNA, (4) a host cell transformed with the replication or the expression vector, (5) a method for producing the polypeptide which comprises culturing the host cells, (6) a monoclonal or polyclonal antibody against the polypeptide, (7) a pharmaceutical composition containing the polypeptide or the antibody, in association with pharmaceutically acceptable excipient and/or antibody, (8) a screening method for a compound having agonistic or antagonistic activity against EP1, comprising using the polypeptide or the host cell. The polypeptide of the present invention can be used for treating diseases, which is caused by over production of PGE2, such as pain, fever and pollakiuria.

Claims2

Dependent claims

A method for screening a compound for antagonistic activity against EP1, comprising the steps of:

(1) contacting a test compound with a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:
1 in the presence of at least 10 nM of PGE2;
(2) detecting intracellular Ca2+ concentration in the cell expressing said polypeptide in the presence and absence of said test compound,
wherein when the intracellular Ca2+ concentration in the presence of said test compound is reduced relative to the intracellular Ca2+ concentration in the absence of said test compound, said test compound is an antagonist of EP1.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

11/470,213Filed 5 Sep 2006 · division

Priority

JP P.2001-08548023 Mar 2001

Published

US 2007/0009514 A111 Jan 2007

Granted

27 Oct 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

G01N 33/88
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing:…
A61P 13/02
Drugs for disorders of the urinary system: of urine or of the urinary tract, e.g. urine acidifiers
A61P 25/04
Drugs for disorders of the nervous system: centrally acting analgesics, e.g. opioids
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents

Prostaglandin receptor EP1

Life of this patent

Prostaglandin receptor EP1

Life of this patent

Abstract

Claims2